The Online Books Page

Pharmaceutical industry -- Environmental aspects -- United States

See also what's at your library, or elsewhere.

• Pharmaceutical industry -- Environmental aspects
• Chemical industry -- Environmental aspects -- United States
• Pharmaceutical industry -- United States

• Pharmaceutical industry -- Waste disposal -- Environmental aspects -- United States

• Profile of the pharmaceutical manufacturing industry (Office of Compliance, Office of Enforcement and Compliance Assurance, U.S. Environmental Protection Agency :, 1997), by United States. Environmental Protection Agency. Office of Compliance (page images at HathiTrust)

• Pollution prevention assessment for a manufacturer of pharmaceuticals (U.S. Environmental Protection Agency, National Risk Management Research Laboratory, 1995), by Harry W. Edwards, Gwen P. Looby, Michael F. Kostrzewa, and National Risk Management Research Laboratory (U.S.) (page images at HathiTrust)
• Analytical methods for the determination of pollutants in pharmaceutical manufacturing industry wastewater. (Washington, D.C. : U.S. Environmental Protection Agency, Office of Water, [1998], 1998), by United States. Environmental Protection Agency. Office of Science and Technology. Engineering and Analysis Division (page images at HathiTrust)

Items below (if any) are from related and broader terms.

• Analytical methods for the determination of pollutants in pharmaceutical manufacturing industry wastewater. (United States Environmental Protection Agency, Office of Water, Engineering and Analysis Division, 1995), by United States. Environmental Protection Agency. Office of Science and Technology. Engineering and Analysis Division (page images at HathiTrust)

• Air oxidation processes in synthetic organic chemical manufacturing industry : background information for proposed standards (U.S. Environmental Protection Agency, Office of Air, Noise, and Radiation, Office of Air Quality Planning and Standards, 1983), by United States. Environmental Protection Agency. Emission Standards and Engineering Division (page images at HathiTrust)
• Chemical manufacturers. (Environmental Protection Agency, Office of Solid Waste, 1990), by United States. Office of Solid Waste (page images at HathiTrust)
• Control of volatile organic compound emissions from air oxidation processes in synthetic organic chemical manufacturing industry (U.S. Environmental Protection Agency, Office of Air and Radiation, Office of Air Quality Planning and Standards, 1984), by United States. Environmental Protection Agency. Emission Standards and Engineering Division (page images at HathiTrust)

• Pollution control : information on chemical industry safety equipment expenditures : fact sheet for the Chairman, Subcommittee on Commerce, Transportation, and Tourism, Committee on Energy and Commerce, House of Representatives (The Office, 1985), by United States General Accounting Office (page images at HathiTrust)

• Protective measures for controlling exposure to cadmium : appendix A. (U.S. Dept. of Labor, Occupational Safety and Health Administration, 1987), by United States. Occupational Safety and Health Administration. Directorate of Technical Support (page images at HathiTrust)

• Sea water corrosion control by environment modification (U.S. Dept. of the Interior, 1969), by Robert A. Legault, Dow Chemical Company, and United States. Office of Saline Water (page images at HathiTrust)

• The uncontrolled export of unregistered pesticides : hearing before the Environment, Energy, and Natural Resources Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred First Congress, first session, May 3, 1989. (U.S. G.P.O. :, 1989), by Energy United States. Congress. House. Committee on Government Operations. Environment (page images at HathiTrust)

• Profile of the plastic resin and manmade fiber industries (Office of Compliance, Office of Enforcement and Compliance Assurance, U.S. Environmental Protection Agency :, 1997), by United States. Environmental Protection Agency. Office of Compliance (page images at HathiTrust)

• Draft environmental impact statement on the Chevron phosphate project (The Bureau, 1983), by Wyoming. Office of Industrial Siting Administration and United States Bureau of Land Management (page images at HathiTrust)

• HR 3970, Green Chemistry Research and Development Act of 2004 (U.S. G.P.O. :, 2004), by United States. Congress. House. Committee on Science (page images at HathiTrust)

• Prices, Markets, and the Pharmaceutical Revolution (Washington: AEI Press, 2000), by John E. Calfee (PDF at AEI)
• Prescription for the People: An Activist's Guide to Making Medicine Affordable for All (Ithaca, NY and London: ILR Press, c2017), by Fran Quigley (PDF and Epub with commentary at Cornell Open)
• Threescore Years and Ten: A Narrative of the First Seventy Years of Eli Lilly and Company, 1876-1946 (Chicago: Lakeside Press, 1946), by Roscoe Collins Clark (page images at HathiTrust)
• Economic report [on] sales, promotion, and product differentiation in two prescription drug markets : staff report to the Federal Trade Commission (For sale by the Supt. of Docs., U.S. Govt. Print. Off.], 1977), by Ronald S. Bond, David Lean, and United States. Federal Trade Commission. Bureau of Economics (page images at HathiTrust)
• Interim reports (The Dept., 1977), by Education United States. Department of Health (page images at HathiTrust)
• Assessment of the Commissioner's report of October 1975 (The Department, 1976), by Education United States. Department of Health (page images at HathiTrust)
• The Commissioner's report of investigation of charges from joint hearings, Subcommittee on Health, Labor and Public Welfare Committee, Subcommittee on Administrative Practice and Procedure, Judiciary Committee, United States Senate, August 15-16, 1974. (Food and Drug Administration?], 1975), by United States Food and Drug Administration and Alexander M. Schmidt (page images at HathiTrust)
• Census of business; 1935. ([Washington, 1937), by United States Bureau of the Census (page images at HathiTrust)
• Report of the Secretary's Review Committee of the Task Force on Prescription Drugs. (Office of the Secretary, U.S. Dept. of Health, Education, and Welfare, 1969), by United States. Secretary's Review Committee of the Task Force on Prescription Drugs (page images at HathiTrust; US access only)
• Final report. (Office of the Secretary, U.S. Dept. of Health, Education, and Welfare; [for sale by the Supt. of Docs., U.S. Govt. Print. Off.], 1969), by United States. Task Force on Prescription Drugs (page images at HathiTrust)
• Competitive problems in the drug industry. Hearings, Ninetieth Congress, first session. ... (U. S. Govt. Print. Off., 1967), by United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly (page images at HathiTrust)
• The drug makers and the drug distributors; background papers. (Office of the Secretary, U.S. Dept. of Health, Education, and Welfare; [for sale by the Supt. of Docs., U.S. Govt. Print. Off.], 1968), by United States. Task Force on Prescription Drugs (page images at HathiTrust; US access only)
• Administered prices: drugs. (U. S. Govt. Print. Off., 1961), by United States Senate Committee on the Judiciary (page images at HathiTrust)
• Economic report on antibiotics manufacture, June 1958. (U. S. Govt. Print. Off., 1958), by United States Federal Trade Commission (page images at HathiTrust)
• Census of American business : 1933. A civil works administration project. Retail distribution. Drug retailing including drug-store chains. May, 1935. ([Washington, 1935], 1935), by United States Bureau of the Census (page images at HathiTrust)
• Is the doctor in? (Exposition Press, 1963), by Rufus L. McQuillan (page images at HathiTrust)
• ... Traffic in narcotic drugs. Report of Special committee of investigation appointed March 25, 1918, by the secretary of the Treasury. June, 1919. (Govt. print. off., 1919), by United States. Department of the Treasury. Special Narcotic Committee, Henry Thomas Rainey, and United States Internal Revenue Service (page images at HathiTrust)
• Interim report[s] (Office of the Secretary, U.S. Dept. of Health, Education and Welfare, 1960), by United States. Task Force on Prescription Drugs (page images at HathiTrust)
• A Competitive assessment of the U.S. pharmaceutical industry (U.S. Dept. of Commerce, International Trade Administration :, 1985), by United States. International Trade Administration. Industry Analysis Division (page images at HathiTrust)
• The basis and development of fair trade (New York, 1946), by National Wholesale Druggists' Association (page images at HathiTrust)
• Effective use of wholesale drug warehouses. (U. S. Govt. Print. Off., 1947), by John Rundell Bromell (page images at HathiTrust)
• Detailing by druggists, a supplement to the book Detailing the physician. For retail druggists. (Romaine Pierson publishers, inc., 1942), by Tom Jones (page images at HathiTrust)
• Poisons and habit-forming drugs. : A digest of laws and regulations relating to the possession, use, sale, and manufacture of poisons and habit-forming drugs enacted during 1912 and 1913, now in force in the United States. (Govt. print. off., 1913), by Martin I. Wilbert, Murray Galt Motter, and United States. Public health service. Public health reports. Reprint 146 (page images at HathiTrust)
• Markets for American pharmaceutical, medicinal, and biological prepartions. (Govt. print. off., 1923), by Bureau of Foreign and Domestic Commerce and United States. Bureau of foreign and domestic commerce (Dept. of commerce) (page images at HathiTrust)
• A plan for action : phase II. (U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, 1987), by United States Food and Drug Administration (page images at HathiTrust)
• Guideline on sterile drug products produced by aseptic processing (U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, 1987), by Center for Drugs and Biologics (U.S.), Center for Drugs and Biologics (U.S.). Office of Compliance. Division of Manufacturing and Product Quality, and United States. Food and Drug Administration. Office of Regulatory Affairs (page images at HathiTrust; US access only)
• Drug regulation reform--oversight hearing before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, second session .... (U.S. G.P.O., 1980), by United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• Competition in the drug industry hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-seventh Congress, first session, March 10, 1981. (U.S. G.P.O., 1981), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• High drug costs for the elderly the need for relief : hearing before the Subcommittee on Human Services of the Select Committee on Aging, House of Representatives, Ninety-eighth Congress, second session, September 10, 1984, Bronx, NY. (U.S. G.P.O., 1984), by United States. Congress. House. Select Committee on Aging. Subcommittee on Human Services (page images at HathiTrust)
• Drug Price Competition and Patent Term Restoration Act of 1984 hearing before the Committee on Labor and Human Resources, United States Senate, Ninety-eighth Congress, second session on S. 2748 ... June 28, 1984. (U.S. G.P.O., 1985), by United States Senate Committee on Labor and Human Resources (page images at HathiTrust)
• Prescription drug price increases hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, first session, July 15, 1985. (U.S. G.P.O., 1986), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• Competitive problems in the pharmaceutical drug industry hearing before the Subcommittee on Antitrust, Monopolies [sic], and Business Rights of the Committee on the Judiciary, United States Senate, One Hundredth Congress, first session, on the generic drug industry and its concerns with respect to competition from the brand name manufacturers, October 21, 1987. (U.S. G.P.O., 1989), by Monopoly United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust (page images at HathiTrust)
• How health care reform affects pharmaceutical research and development (The Office, 1994), by Anna Cook, Philip Webre, and United States Congressional Budget Office (page images at HathiTrust)
• Competitive problems in the drug industry hearings before Subcommittee on Monopoly and Anticompetitive Activities of the Select Committee on Small Business, United States Senate, Ninetieth Congress, first session ... (U.S. Govt. Print. Off., 1967), by United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly and Anticompetitive Activities and United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly (page images at HathiTrust)
• Pricing of drugs, 1977 joint hearing before the Subcommittee on Health and Scientific Research of the Committee on Human Resources and the Subcommittee on Antitrust and Monopoly of the Committee on the Judiciary, United States Senate, 95th Congress, first session ... July 14, 1977. (U.S. Govt. Print. Off., 1977), by United State Senate Subcommittee on Health and Scientific Research and United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust and Monopoly (page images at HathiTrust)
• Contempt proceedings against Secretary of HEW, Joseph A. Califano, Jr. : business meeting of the Subcommittee on Oversight and Investigations of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-fifth Congress, second session. (U.S. Govt. Print. Off., 1979), by United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Polydrug abuse-the response of the medical profession and the pharmaceutical industry : a report of the Select Committee on Narcotics Abuse and Control, Ninety-fifth Congress, second session. (U.S. G.P.O. :, 1979), by United States. Congress. House. Select Committee on Narcotics Abuse and Control (page images at HathiTrust)
• Competitive problems in the drug industry : drug testing : summary and analysis (U.S. Govt. Print. Off., 1979), by Library of Congress. Congressional Research Service, Vikki A. Zegel, Janet E. Lemke, and United States. Congress. Senate. Select Committee on Small Business (page images at HathiTrust)
• "Man-in-the-plant" revisited, a deceptive drug labeling practice continues hearing before the Subcommittee on Oversight and Investigations of the Committee on Interstate and Foreign Committee, House of Representatives, Ninety-sixth Congress, second session, March 6, 1980. (U.S. Govt. Print. Off., 1980), by United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• The Distribution of illegal incident characteristics : cases of bank fraud and embezzlement, computer-related crime, and insider theft from drug manufacturers and distributors (The Commission :, 1980), by Lawrence Livermore Laboratory, Fuel Cycle U.S. Nuclear Regulatory Commission. Division of Safeguards, and J.M. Heineke and Associates (page images at HathiTrust)
• Pharmaceutical industry : hazardous waste generation, treatment, and disposal. (U.S. Environmental Protection Agency, 1976), by United States Environmental Protection Agency (page images at HathiTrust)
• Competitive problems in the drug industry summary and analysis (U.S. Govt. Print. Off., 1972), by Library of Congress. Education and Public Welfare Division, Glenn R. Markus, and United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly (page images at HathiTrust)
• Competitive problems in the drug industry Federal drug procurement and purchase policies, summary and analysis : [prepared for] Select Committee on Small Business, United States Senate, Subcommittee on Monopoly (U.S. Gov. Print. Off., 1974), by Library of Congress. Education and Public Welfare Division, Jack Ebeler, Glenn R. Markus, and United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly (page images at HathiTrust)
• User fees for prescription drugs : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, second session, August 10, 1992. (U.S. G.P.O. :, 1992), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• User fees for prescription drugs : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, second session, August 10, 1992. (U.S. G.P.O. :, 1992), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• User fees for the Food and Drug Administration : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Second session, on examining proposed legislation to authorize the Food and Drug Administration to charge user fees to prescription drug manufacturers to increase resources to improve the review time on drug applications, September 22, 1992. (U.S. G.P.O. :, 1992), by United States Senate Committee on Labor and Human Resources (page images at HathiTrust)
• Skyrocketing prescription drug prices : hearings before the Special Committee on Aging, United States Senate, One Hundred First Congress, first session, Washington, DC ... July 18, 1989 ... November 16, 1889. (U.S. G.P.O. :, 1990), by United States Senate Special Committee on Aging (page images at HathiTrust)
• Pharmaceutical marketplace reform : is competition the right prescription? : hearing before the Special Committee on Aging, United States Senate, One Hundred Third Congress, first session, Washington, DC, November 16, 1993. (U.S. G.P.O. :, 1994), by United States Senate Special Committee on Aging (page images at HathiTrust)
• Perspectives on pharmaceutical pricing practices : hearing before the Subcommittee on Oversight and Investigations of the Committee on Commerce, House of Representatives, One Hundred Fourth Congress, second session, September 19, 1996. (U.S. G.P.O. :, 1996), by United States House Committee on Commerce, Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Rx for generic drug safety : accurate information for older Americans : hearing before the Subcommittee on Housing and Consumer Interests of the Select Committee on Aging, House of Representatives, One Hundred First Congress, second session, March 1, 1990. (U.S. G.P.O. :, 1990), by United States. Congress. House. Select Committee on Aging. Subcommittee on Housing and Consumer Interests (page images at HathiTrust)
• The federal government's investment in new drug research and development : are we getting our money's worth? : hearing before the Special Committee on Aging, United States Senate, One Hundred Third Congress, first session, Washington, DC, February 24, 1993. (U.S. G.P.O. :, 1993), by United States Senate Special Committee on Aging (page images at HathiTrust)
• Drug pricing : poor prescription for consumers and taxpayers? : hearing before the Committee on Governmental Affairs, United States Senate, One Hundred Third Congress, second session, July 27, 1994. (U.S. G.P.O. :, 1995), by United States Senate Committee on Governmental Affairs (page images at HathiTrust)
• FDA medical product approvals : hearing before the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, August 8, 1995. (U.S. G.P.O. :, 1997), by Natural Resources United States. Congress. House. Committee on Government Reform and Oversight. Subcommittee on National Economic Growth (page images at HathiTrust)
• Early results on ventures with drug manufacturer (The Office ;, 1995), by United States General Accounting Office (page images at HathiTrust)
• FEHBP plans satisfied with savings and services, but retail pharmacies have concerns (The Office ;, 1997), by United States General Accounting Office (page images at HathiTrust)
• Companies typically charge more in the United States than in the United Kingdom (The Office ;, 1994), by United States General Accounting Office and United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry (The Office, 1998), by Anna Cook, Elliot Schwartz, Jan Paul Acton, and United States Congressional Budget Office (page images at HathiTrust)
• The economic aspects of the pharmaceutical industry in the United States : hearing before the Subcommittee on Human Rights and Wellness of the Committee on Government Reform, House of Representatives, One Hundred Eighth Congress, first session, June 25, 2003. (U.S. G.P.O. :, 2003), by United States. Congress. House. Committee on Government Reform. Subcommittee on Human Rights and Wellness (page images at HathiTrust)
• Generic pharmaceuticals : marketplace access and consumer issues : hearing before the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Seventh Congress, second session, April 23, 2002. (U.S. G.P.O. :, 2004), by United States Senate Committee on Commerce, Science, and Transportation (page images at HathiTrust)
• Avoiding conflicts of interest at the National Institutes of Health : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Eighth Congress, second session, special hearing, January 22, 2004, Washington, DC. (U.S. G.P.O. :, 2004), by Health and Human Services United States. Congress. Senate. Committee on Appropriations. Subcommittee on Departments of Labor (page images at HathiTrust)
• International trade and pharmaceuticals : joint hearing before the Subcommittee on International Trade and the Subcommittee on Health Care of the Committee on Finance, United States Senate, One Hundred Eighth Congress, second session, April 27, 2004. (U.S. G.P.O. :, 2004), by United States. Congress. Senate. Committee on Finance. Subcommittee on International Trade and United States. Congress. Senate. Committee on Finance. Subcommittee on Health Care (page images at HathiTrust)
• A report on the aspects of concentration and product obsolescence in the pharmaceutical industry in the United States. [Prepared by Richard D. Mannis and others] December 4, 1961. C-64195-2. ([s.n.], 1961), by Inc Arthur D. Little and Richard D. Mannis (page images at HathiTrust)
• Fifteenth census of the United States. Census of distribution. Retail distribution. (Trade series) Drug retailing .. (U. S. Govt. print. off., 1933), by United States Bureau of the Census and Charles F. Beach (page images at HathiTrust)
• Speeding access to affordable life-saving drugs (U.S. G.P.O. :, 2006), by United States Senate Special Committee on Aging (page images at HathiTrust)
• Paying off generics to prevent competition with brand name drugs : should it be prohibited? : hearing before the Committee on the Judiciary, United States Senate, One Hundred Tenth Congress, first session, January 17, 2007. (U.S. G.P.O. :, 2007), by United States Senate Committee on the Judiciary (page images at HathiTrust)
• Food and Drug Administration's Critical Path Initiative : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Tenth Congress, first session, special hearing, June 1, 2007, Salt Lake City, Utah. (U.S. G.P.O. :, 2008), by Rural Development United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture (page images at HathiTrust)
• The drug story; a factological history of America's $10,000,000,000 drug cartel -- its methods, operations, hidden ownership, profits and terrific impact on the health of the American people. (Columbia Pub. Co., 1949), by Morris Allison Bealle (page images at HathiTrust)
• Global competitiveness of U.S. advanced-technology manufacturing industries : pharmaceuticals : report to the Committee on Finance, United States Senate, on investigation no. 332-302 under section 332(g) of the Tariff Act of 1930 (U.S. International Trade Commission, 1991), by Edmund Cappuccilli, Norman McLennan, Donald Alexander, United States International Trade Commission, and United States. Congress. Senate. Committee on Finance (page images at HathiTrust)
• From test tube to patient : new drug development in the United States. (Dept. of Health & Human Services, Public Health Service, Food and Drug Administration, 1988), by United States Food and Drug Administration (page images at HathiTrust)
• The professional pharmacy; an analysis of prescription department activities; part of the national drug store survey. (American Pharmaceutical Assn., 1935), by Frank Anthony Delgado and United States Bureau of Foreign and Domestic Commerce (page images at HathiTrust)
• Fifty years, commemorating the fiftieth anniversary of the founding of Lehn & Fink, inc. (Lehn & Fink, Inc., 1924), by George M. Murray (page images at HathiTrust)
• Earning a failing grade : a report card on 1992 drug manufacturer price inflation : staff report to the Special Committee on Aging, United States Senate. (U.S. G.P.O. :, 1993), by United States Senate Special Committee on Aging (page images at HathiTrust)
• The federal government's investment in new drug research and development : are we getting our money's worth? : hearing before the Special Committee on Aging, United States Senate, One Hundred Third Congress, first session, Washington, DC, February 24, 1992. (U.S. G.P.O. :, 1993), by United States Senate Special Committee on Aging (page images at HathiTrust)
• Prescription drug costs : the growing burden for older Americans : hearing before the Special Committee on Aging, United States Senate, One Hundredth Congress, first session, Little Rock, AR, August 27, 1987. (U.S. G.P.O. :, 1988), by United States Senate Special Committee on Aging (page images at HathiTrust)
• Generic pharmaceuticals : marketplace access and consumer issues : hearing before the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Seventh Congress, second session, April 23, 2002. (U.S. G.P.O. :, 2004), by United States Senate Committee on Commerce, Science, and Transportation (page images at HathiTrust)
• Prescription drug price increases : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, first session, July 15, 1985. (U.S. G.P.O., 1986), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• Prescription drug diversion and counterfeiting : hearings before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, first-[second] session. (U.S. G.P.O., 1986), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Export of unapproved drugs : hearing before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, second session, on H.R. 3962 and H.R. 3995 ... April 28, 1986. (U.S. G.P.O. :, 1986), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• Safety and soundness standards in the mail order prescription industry : hearings before the Subcommittee on Government Efficiency, Federalism, and the District of Columbia of the Committee on Governmental Affairs, United States Senate, One Hundredth Congress, first session, August 5, 6, 1987. (U.S. G.P.O. :, 1987), by Federalism United States. Congress. Senate. Committee on Governmental Affairs. Subcommittee on Government Efficiency (page images at HathiTrust)
• Proceedings of... annual meeting ([New York?], 1912), by American Drug Manufacturers Association (page images at HathiTrust)
• Competitive problems in the pharmaceutical drug industry : hearing before the Subcommittee on Antitrust, Monopolies [sic], and Business Rights of the Committee on the Judiciary, United States Senate, One Hundredth Congress, first session, on the generic drug industry and its concerns with respect to competition from the brand name manufacturers, October 21, 1987. (U.S. G.P.O. :, 1989), by Monopoly United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust (page images at HathiTrust)
• The licit importation of opium : hearing before the Subcommittee on Crime of the Committee on the Judiciary, House of Representatives, One Hundred First Congress, second session, February 27, 1990. (U.S. G.P.O. :, 1990), by United States. Congress. House. Committee on the Judiciary. Subcommittee on Crime (page images at HathiTrust)
• FDA Export Reform and Enhancement Act of 1995 : hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, One Hundred Fourth Congress, first session on S. 593 ... July 13, 1995. (U.S. G.P.O. :, 1995), by United States. Congress. Senate. Committee on Labor and Human Resources. Subcommittee on Aging (page images at HathiTrust)
• Drug Price Competitition and Patent Term Restoration Act of 1984 : hearing before the Committee on Labor and Human Resources, United States Senate, Ninety-eighth Congress, second session on S. 2748 ... June 28, 1984. (U.S. G.P.O., 1984), by United States Senate Committee on Labor and Human Resources (page images at HathiTrust)
• Competitive problems in the drug industry : Hearings, Ninetieth Congress, first session ... (U.S. Govt. Print. Off., 1967), by United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly (page images at HathiTrust)
• U.S. international trade performance and outlook : competitive position in the automotive, aerospace, and chemical and pharmaceutical sectors : hearings before the Subcommittee on Trade of the Committee on Ways and Means, House of Representatives, One Hundred Second Congress, second session, March 11, 23, 30, 31; and April 7, 1992. (U.S. G.P.O. :, 1992), by United States. Congress. House. Committee on Ways and Means. Subcommittee on Trade (page images at HathiTrust)
• Oversight of the Food and Drug Administration's progress in reducing unnecessary paperwork burdens upon small business : hearing before the Subcommittee on Government Programs of the Committee on Small Business, House of Representatives, One Hundred Fourth Congress, second session, Washington, DC, July 24, 1996. (U.S. G.P.O. :, 1997), by United States. Congress. House. Committee on Small Business. Subcommittee on Government Programs (page images at HathiTrust)
• Pricing of drugs codeveloped by federal laboratories and private companies : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, first session, Washington, DC, January 25, 1993. (U.S. G.P.O. :, 1993), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)
• Are patent settlements that delay generic drug market entry anticompetitive (U.S. G.P.O. :, 2010), by United States. Congress. House. Committee on the Judiciary. Subcommittee on Courts and Competition Policy (page images at HathiTrust)
• The drug users. (Office of the Secretary, U.S. Dept. of Health, Education, and Welfare, 1968), by United States. Task Force on Prescription Drugs (page images at HathiTrust)
• Food and drug act amendment, relating to exports. Hearings, Eighty-first Congress, first session on H.R. 562. July 25 and August 8, 1950. (U. S. Govt. Print. Off., 1950), by United States Senate Committee on Interstate and Foreign Commerce (page images at HathiTrust)
• Preclinical and clinical testing by the pharmaceutical industry, 1975- : joint hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-fourth Congress, first session- on examination of the process of drug testing and FDA's role in the regulation and conditions under which such testing is carried out. (U. S. Govt. Print. Off., 1976), by United States Senate Committee on Labor and Public Welfare and United States Senate Committee on the Judiciary (page images at HathiTrust)
• Legislative proposal to increase funding for medical research : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Fifth Congress, first session, special hearing. (U.S. G.P.O. :, 1998), by Health and Human Services United States. Congress. Senate. Committee on Appropriations. Subcommittee on Departments of Labor (page images at HathiTrust)
• Regulation of new drug R. & D. by the Food and Drug Administration,1974 : joint hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-third congress, second session on examination of new drug research and development by the Food and Drug Administration, September 25 and 27, 1974. -- (U. S. Govt. Print. Off., 1975), by United States Senate Committee on Labor and Public Welfare and United States Senate Committee on the Judiciary (page images at HathiTrust; US access only)
• Regulations 51 relating to excise taxes on toilet and medicinal articles under section 907 of the Revenue Act of 1918 (Govt. Print. Off., 1920), by United States. Bureau of Internal Revenue (page images at HathiTrust)
• Interim trade name index of all prescription drugs in the drug efficacy study <May 1, 1976- > (U.S. Dept. of Health, Education, and Welfare, Public Health Service, Food and Drug Administration, Bureau of Drugs., in the 20th century), by United States. Food and Drug Administration. Drug Efficacy Study Implementation Project, Education United States. Dept. of Health, United States Public Health Service, and United States. Food and Drug Administration. Bureau of Drugs (page images at HathiTrust)
• How to improve the procurement and supply of drugs in the Federal Government; report to the Congress [on the] Department of Defense, Veterans Administration, Department of Health, Education, and Welfare, Office of Management and Budget [and] General Services Administration ([Washington, 1973), by United States General Accounting Office (page images at HathiTrust)
• Competition in the pharmaceutical marketplace : antitrust implications of patent settlements : hearing before the Committee on the Judiciary, United States Senate, One Hundred Seventh Congress, first session, May 24, 2001. (U.S. G.P.O. :, 2002), by United States Senate Committee on the Judiciary (page images at HathiTrust)
• Preclinical and clinical testing by the pharmaceutical industry, 1979 : hearing before the Subcommittee on Health and Scientific Research of the Committee on Labor and Human Resources, United States Senate, Ninety-sixth Congress, first session, on examination of the process of drug testing and FDA's role in the process, October 11, 1979. (U.S. Govt. Print. Off. :, 1979), by United States. Congress. Senate. Committee on Labor and Human Resources. Subcommittee on Health and Scientific Research and United States Food and Drug Administration (page images at HathiTrust)
• Competitive problems in the drug industry : drug testing : summary and analysis, Select Committee on Small Business, United States Senate (U.S. Govt. Print. Off. :, 1979), by Library of Congress. Congressional Research Service and United States. Congress. Senate. Select Committee on Small Business (page images at HathiTrust)
• Wages and hours in drugs and medicines and in certain toilet preparations (U.S. Govt. Print. Off., 1939), by Arthur T. Sutherland (page images at HathiTrust)
• Changes in prices for selected drugs (The Office ;, 1992), by United States General Accounting Office (page images at HathiTrust)
• Prescription drug prices : analysis of Canada's Patented Medicine Prices Review Board : report to the Chairman, Special Committee on Aging, U.S. Senate (The Office ;, 1993), by United States General Accounting Office and United States Senate Special Committee on Aging (page images at HathiTrust)
• In the matter of doxycycline : investigation no. 337-TA-3. (U.S. International Trade Commission, 1979), by United States International Trade Commission (page images at HathiTrust)
• Furazolidone (The Commission, 1969), by United States Tariff Commission (page images at HathiTrust)
• Retail diversion of legal drugs : a major problem with no easy solution : report to the Congress (General Accounting Office, 1978), by United States General Accounting Office (page images at HathiTrust)
• Ampicillin; report to the President on preliminary inquiry into complaint under section 337 of the Tariff act of 1930. (Washington, 1970), by United States Tariff Commission (page images at HathiTrust; US access only)
• Code of fair competition for the retail drug trade : compilation of provisions relating to the retail drug trade taken from the Code of fair competition for the retail trade approved by President Roosevelt on October 31, 1933. (U.S. G.P.O., 1933), by United States National Recovery Administration (page images at HathiTrust)
• Code of fair competition for the retail drug industry as revised August 26, 1933. (U.S. Government Printing Office, 1933), by United States National Recovery Administration (page images at HathiTrust)
• Generic drug entry prior to patent expiration (U.S. G.P.O. :, 2002), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health (page images at HathiTrust)
• Diet pill industry. Hearings, Ninetieth Congress, second session, pursuant to S. Res. 26. (U.S. Govt. Print. Off., 1968), by United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust and Monopoly (page images at HathiTrust)
• Shortages of prescription drugs, 1974 : joint hearing before the Subcommittee on Health of the Committee on Labor and Public Welfare, and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-third Congress, second session ... December 5, 1974. (U.S. Govt. Print. Off., 1975), by United States. Congress. Senate. Committee on Labor and Public Welfare. Subcommittee on Health and United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Administrative Practice and Procedure (page images at HathiTrust)
• 1922 guide, intoxicants, industrial alcohol and narcotics (Washington, D.C., 1921), by Lawrence Law Service, Olive Beatty, Chicago McCabe & Tressler, and United States (page images at HathiTrust)
• Examination of the pharmaceutical industry, 1973-74 : hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare, United States Senate, Ninety-third Congress, first and second sessions, on S. 3441 and S. 966. (U.S. Govt. Print. Off, 1974), by United States. Congress. Senate. Committee on Labor and Public Welfare. Subcommittee on Health (page images at HathiTrust)
• Food and drug act amendment, relating to exports : Hearings before the Conmmittee on Interstate and Foreign Commerce, United States, Senate, Eighty-first Congress, first session, on H.R. 562, an act to amend section 801 (d) of the Federal Food, drug and cosmetic act, as amended, in relation to exports. July 25 and August 8, 1949. (G.P.O., 1950), by United States Senate Committee on Interstate and Foreign Commerce (page images at HathiTrust)
• You and your foods, drugs and cosmetics (U.S. Department of Health, Education, and Welfare, Food and Drug Administration, 1956), by United States Food and Drug Administration and Association of Food and Drug Officials of the United States (page images at HathiTrust)
• Competition in the drug industry : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-seventh Congress, first session, March 10, 1981. (U.S. G.P.O., 1981), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Policy implications of pharmaceutical importation for U.S. consumers : hearing before the Subcommittee on Interstate Commerce, Trade, and Tourism of the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Tenth Congress, first session, March 7, 2007. (U.S. G.P.O. :, 2013), by Science United States. Congress. Senate. Committee on Commerce (page images at HathiTrust)
• Small business problems in the drug industry. : Hearings ... House of Representatives, Ninetieth Congress, first session, pursuant to H. Res. 53, a resolution creating a select committee to conduct studies and investigations of the problems of small business, Washington, D. C., April 3, 4, 5, 10, and 12, 1967. (U. S. Govt. Print. Off, 1968), by United States. Congress. House. Select Committee on Small Business. Subcommittee on Activities of Regulatory Agencies (page images at HathiTrust)
• Bureau of narcotics. : Hearings before the Committee on Ways and Means, House of Representatives, Seventy-first Congress, second session, on H.R. 10561, a bill to create in the Treasury Department a Bureau of Narcotics, and for other purposes. March 7 and 8, 1930. (U.S. Govt. Print. Off, 1930), by United States. Congress. House. Committee on Ways and Means (page images at HathiTrust)
• Prescription drug diversion : combating the scourge : hearing before the Subcommittee on Commerce, Manufacturing, and Trade of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, March 1, 2012. (Washington : U.S. Government Printing Office, 2013., 2013), by Manufacturing United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Commerce (page images at HathiTrust)
• Aids to compliance for the drug industry : speeches, exhibits, publications, workshops, posters, audiovisuals (The Administration, 1972), by United States. Food and Drug Administration. Bureau of Drugs. Division of Industry Liaison (page images at HathiTrust)
• Facts about drug wholesaling. (Washington, D.C. : U.S. Department of Commerce, Business and Defense Services Administration, Office of Consumer Goods, 1969., 1969), by United States. Business and Defense Services Administration (page images at HathiTrust)
• Administered prices: drugs. : Report of the Committee on the Judiciary, United States Senate, made by its Subcommittee on Antitrust and Monopoly, pursuant to S. Res. 52, Eighty-seventh Congress, first session, together with individual views to study the Antitrust laws of the United States, and their administration, interpretation, and effect (U.S. Govt. Print. Off, 1961), by United States Senate Committee on the Judiciary (page images at HathiTrust)
• Distribution through drug channels in the 84 wholesale trading areas. Facts important to the manufacturer on the coverage of independent drug stores (The National wholesale druggists' association, 1935), by National Wholesale Druggists' Association (page images at HathiTrust; US access only)
• Sales management guide ... (National wholesale druggists' association, 1942), by Herman C. Nolen and National Wholesale Druggists' Association. Committee on Sales Management (page images at HathiTrust; US access only)
• Review Panel on New Drug Regulation : interim reports. ([Washington, D.C. : The Dept.], 1977), by Education United States. Department of Health (page images at HathiTrust)
• Defense procurement of foreign-made drugs; Military Operations Subcommittee staff memorandum, with Federal agency and other commentary . . . (U.S. Govt. Print. Off., 1962), by United States House Committee on Government Operations (page images at HathiTrust)
• Task force on prescription drugs : final report. (the Dept.; for sale by the Supt. of Docs., U.S. Govt. Print. Off., 1969), by Education United States. Department of Health (page images at HathiTrust; US access only)
• FDA introduction to total drug quality. ([Rockville, Md.] : [U.S. Dept. of Health, Education, and Welfare, Public Health Service, Food and Drug Administration]] ; [[Washington] : [For sale by the Supt. of Docs., U.S. Govt. Print.], [1973], 1973), by United States Food and Drug Administration (page images at HathiTrust)
• Preliminary report of the survey on drugs for rare disease (U.S. G.P.O., 1982), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment (page images at HathiTrust)
• Wholesale druggists' operations : a case study (U.S. G.P.O., 1934), by Edward Joseph Carroll and United States Bureau of Foreign and Domestic Commerce (page images at HathiTrust)
• The traffic in habit-forming narcotic drugs. Statement of the attitude of the United States with documents relating thereto. (Govt. print. off., 1923), by United States. Dept. of State (page images at HathiTrust)
• Opium, the demon flower (Montrose publishing co., distributed by World foundation for public enlightenment on traffic in opium, 1928), by Sara Graham Mulhall (page images at HathiTrust; US access only)
• Wholesale drug industry (United States Government Printing Office, 1933), by United States National Recovery Administration (page images at HathiTrust)
• Pharmaceutical and biological industry (United States Government Printing Office, 1934), by United States National Recovery Administration (page images at HathiTrust)
• Package medicine industry (United States Government Printing Office, 1934), by United States National Recovery Administration (page images at HathiTrust)
• Package medicine industry (United States Government Printing Office, 1934), by United States National Recovery Administration (page images at HathiTrust)
• Prescription drug advertising to consumers : staff report (U.S. G.P.O., 1984), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Price information for drug products: invoice level prices. (Dept. of Health, Education, and Welfare, Health Care Financing Administration.), by United States. Health Care Financing Administration (page images at HathiTrust)
• U.S. Task force on prescription drugs : reports. (U.S. Dept. of Health, Education and Welfare, 1968), by United States Department of Health, Education, and Welfare (page images at HathiTrust)
• Industrial corporation reports. ([Washington], 1941), by United States Federal Trade Commission (page images at HathiTrust; US access only)
• DEA registration information (DEA, 1975), by United States. Drug Enforcement Administration (page images at HathiTrust)
• Drug diversion : prescription drug diversion and the American consumer : what you think you see may not be what you get : a staff report (U.S. G.P.O., 1985), by United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations (page images at HathiTrust)
• Proceedings of the conference of representatives of medical, dental, pharmaceutical, and veterinary associations and other scientific associations and agencies with the surgeon general of the United States Public health service held at Washington, D. C., August 12, 1930. (U. S. Govt. print. off., 1931), by D.C.) Conference on Medicinal and Scientific Requirements of Narcotic Drugs (1930 : Washington (page images at HathiTrust; US access only)
• Manufacture of methamphetamine and other restricted dangerous drugs : a report to the 1971 Legislature pursuant to 1970 House resolution 266. (s.n.], 1971), by California. Department of Public Health (page images at HathiTrust; US access only)
• Second interim report and recommendations, August 30, 1968. (Office of the Secretary, U.S. Dept. of Health, Education, and Welfare, 1968), by United States. Task Force on Prescription Drugs (page images at HathiTrust)
• Drug shortage crisis : lives are in the balance : hearing before the Subcommittee on Health Care, District of Columbia, Census, and the National Archives of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Twelfth Congress, first session, November 30, 2011 (U.S. G.P.O. :, 2012), by District of Columbia United States. Congress. House. Committee on Oversight and Government Reform. Subcommittee on Health Care (page images at HathiTrust)
• The drug story : a factological history of America's $10,000,000,000 drug cartel--its methods, operations, hidden ownership, profits and terrific impact on the health of the American people (Columbia Pub. Co., 1949), by Morris A. Bealle (page images at HathiTrust; US access only)
• Third interim report : coverage of drugs under Medicare. (U.S. G.P.O., 1969), by United States. Task Force on Prescription Drugs (page images at HathiTrust)
• Final report. (U.S. Gov't. Print Off., 1963), by United States. President's Advisory Commission on Narcotic and Drug Abuse (page images at HathiTrust; US access only)
• Competitive problems in the drug industry. (U.S. Gov't Print. Off., 1967), by United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly (page images at HathiTrust)
• Traffic in narcotic drugs. (Govt. print. off., 1919), by United States. Dept. of the Treasury. Special narcotic committee, Henry Thomas Rainey, and United States. Office of Internal Revenue (page images at HathiTrust)
• Task force on prescription drugs : second interim report and recommendations, August 30, 1968 - a critique. (U.S. G.P.O.], 1968), by Pharmaceutical Manufacturers Association (page images at HathiTrust)

More items available under broader and related terms at left.